Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?.
- Author:
Joo Hyun LEE
1
;
Soo Kyung CHO
;
Minkyung HAN
;
Dam KIM
;
Sang Cheol BAE
;
Yoon Kyoung SUNG
Author Information
1. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Glucocorticoids;
Osteoporosis;
Arthritis, rheumatoid;
Guideline
- MeSH:
Aged;
Arthritis, Rheumatoid/diagnosis/*drug therapy;
Bone Density Conservation Agents/*therapeutic use;
*Decision Support Techniques;
Female;
Glucocorticoids/*adverse effects;
Hospitals, University;
Humans;
Middle Aged;
Osteoporosis/*chemically induced/diagnosis/*prevention & control;
Osteoporotic Fractures/chemically induced/prevention & control;
Patient Selection;
Practice Guidelines as Topic;
Predictive Value of Tests;
Prospective Studies;
Republic of Korea;
Risk Assessment;
Risk Factors;
Spinal Fractures/chemically induced/prevention & control
- From:The Korean Journal of Internal Medicine
2014;29(4):509-515
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: We investigated differences in identifying candidates for antiosteoporotic treatment in rheumatoid arthritis (RA) patients according to two available clinical guidelines. METHODS: We prospectively enrolled 100 female patients aged 50 years or older with RA who visited Hanyang University Hospital for periodic examinations between April 2011 and August 2011. We applied the glucocorticoid-induced osteoporosis (GIOP) recommendations and the National Osteoporosis Foundation (NOF) guidelines to RA patients and examined agreement between the guidelines for identifying candidates for antiosteoporotic treatment. We also analyzed the impact of screening vertebral fractures (VFs) in determining the treatment of osteoporosis in RA patients. RESULTS: The 57 patients taking glucocorticoids were classified into high-risk (n = 23), medium-risk (n = 16), and low-risk (n = 18) groups according to the GIOP recommendations. Based on the NOF guidelines, 36 of 57 patients were candidates for antiosteoporotic treatment and the agreement between two guidelines was high (kappa = 0.76). Two of the 18 patients in the low-risk group and 19 of 43 patients not eligible per the GIOP recommendations were classified as candidates for antiosteoporotic treatment by the NOF guidelines. CONCLUSIONS: In determining antiosteoporotic treatment for RA patients, using only the GIOP recommendations is insufficient. Application of the NOF guidelines in patients not eligible for or classified into the low-risk group per the GIOP recommendations and screening for VFs may be helpful in deciding on antiosteoporotic treatment in RA patients.
